ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

WSJ BLOG/Health: FDA OKs New Treatment for Soft-Tissue Sarcoma Patients

(This story has been posted on The Wall Street Journal Online's Health Blog at By Jennifer Corbett Dooren Patients with soft-tissue sarcoma, a rare cancer that starts in the body's muscle or connective tissues, now have a new treatment option. The FDA late yesterday approved GlaxoSmithKline's drug Votrient for use in patients with soft-tissue sarcoma, Dow Jones Newswires reports. This is the first new treatment in decades for the cancer. The National Cancer Institute estimates 11,000 cases of soft tissue sarcoma are diagnosed each year in the U.S. Votrient, a tablet taken orally, is already on the U.S. market to treat advanced kidney cancer. It was approved to treat several subtypes of advanced soft-tissue sarcoma, after prior chemotherapy. Votrient's approval follows the March recommendation of an agency advisory panel that the drug's benefits outweighed its risks. Clinical data involving 369 patients showed the drug temporarily slowed tumor growth but it isn't clear if the drug prolongs lives. And the FDA notes that Votrient carries the agency's toughest warning on its label, telling patients and doctors about the potentially fatal liver damage. Patients should be monitored for liver function and treatment halt if liver function declines, the agency says. Separately Thursday, the FDA granted wider approval to Novartis's Afinitor to treat non-cancerous kidney tumors that don't require immediate surgery. Afinitor was first approved in the U.S. in 2009 to treat kidney cancer after treatment with other drugs fail. Afinitor was approved to treat kidney tumors that are caused by a rare genetic disease called tuberous sclerosis complex, or TSC, which affects about 40,000 Americans. -For continuously updated news from The Wall Street Journal, see at

Stock News for Novartis (NVS)
11/25/201511:30:00Prescription Skin Drugs Explode in Costs, Study Shows
11/23/201509:20:02The FDA Approves Exelixis, Inc's New Cancer Drug
11/23/201508:46:033 Dividend Stocks You Don't Have to Babysit
11/20/201517:35:00Novartis Finalizes Settlement With Justice Department
11/20/201508:41:03How 1 Specialty-Drug Maker Hopes to Win Back Investor Trust
11/19/201509:16:045 Things GlaxoSmithKline PLC Wants You to Know
11/17/201511:40:56Why Ophthotech Corporation's Shares Soared in October
11/07/201513:40:09Momenta Slowed (Temporarily)
11/06/201512:16:03Why XOMA Shares Are Crashing
11/04/201510:20:02Is This Drug Going to Be a Big Threat to Biogen and Novartis...
11/01/201511:23:035 Healthcare Trends to Invest in for the Next 20 Years
10/31/201509:21:03Generic Copaxone Isn't Derailing Teva Pharmaceuticals...Yet
10/29/201516:07:02GlaxoSmithKline's Diverging Q3 Results Imply a Long Road to Recovery
10/28/201509:20:00GlaxoSmithKline Sees Higher Sales
10/28/201509:03:00GlaxoSmithKline Sees Higher Sales in Third Quarter But Lower...
10/27/201511:15:00Novartis Profit Hurt by U.S. Settlement -- 4th Update
10/27/201507:49:00Novartis Profit Hurt by U.S. Settlement-- Third Update
10/27/201505:50:00Global Stocks Fall Ahead of Fed Meeting
10/27/201505:05:00Novartis Profit Hurt by U.S. Settlement -- 2nd Update
10/27/201504:57:00Novartis Profit Hurt by U.S. Settlement -- Update

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations